ライフサイエンスコーパス: polycystic liver disease

1 presents a potential therapeutic approach in polycystic liver disease.

2 Mutations in polycystins are a cause of polycystic liver disease.

3 tal diseases including Alagille Syndrome and polycystic liver disease.

4 gous gene models of human autosomal dominant polycystic liver disease.

5 ibitors might be used to treat patients with polycystic liver disease.

6 ese proteins might inhibit cyst expansion in polycystic liver disease.

7 regulator of cell proliferation may underlie polycystic liver disease.

8 mortalized B lymphoblasts from patients with polycystic liver disease.

9 mic reticulum (ER), cause autosomal dominant polycystic liver disease.

10 d in livers of animal models and humans with polycystic liver disease.

11 Mutations in PC2 are associated with polycystic liver diseases.

12 ts with breast abnormalities, 1 patient with polycystic liver disease, 1 patient with esophageal thic

13 Autosomal dominant polycystic liver disease (ADPLD) is a distinct clinical

14 nical profile of isolated autosomal dominant polycystic liver disease (ADPLD) using nonaffected famil

15 one of the genes causing autosomal dominant polycystic liver disease (ADPLD).

16 ficant cause of ESRD, and autosomal dominant polycystic liver diseases (ADPLD), which result in signi

17 in vitro key features of Alagille syndrome, polycystic liver disease and cystic fibrosis (CF)-associ

18 olycystic kidney disease, autosomal dominant polycystic liver disease, and the third form of ADPKD.

19 al history, manifestations, and treatment of polycystic liver disease are based on the disease as it

20 underdiagnosed and genetically distinct from polycystic liver disease associated with ADPKD but with

21 y-eight of the 49 individuals diagnosed with polycystic liver disease before participation in the stu

22 Severe polycystic liver disease can complicate adult dominant p

23 ith extensive hepatic involvement with adult polycystic liver disease can have an excellent outcome w

24 Polycystic liver disease, commonly associated with polyc

25 In polycystic liver diseases, cyst formation involves chola

26 whereas in isolated PCLD (autosomal dominant polycystic liver disease), disrupted cell adhesion may b

27 osomal dominant polycystic kidney disease or polycystic liver disease; efficacy does not depend on si

28 hird gene yielding isolated liver cysts (the polycystic liver disease gene).

29 ative or indeterminate diagnosis, those with polycystic liver disease had slightly higher levels of s

30 Surgical intervention for symptomatic polycystic liver disease has been associated with signif

31 hich resulted in a slow, progressive form of polycystic liver disease in adult mice.

32 Mutations in the gene encoding SEC63 cause polycystic liver disease in humans; however, it is not c

33 al presentation and histological features of polycystic liver disease in the presence or absence of A

34 Genetically, polycystic liver disease is a heterogeneous disorder wit

35 Polycystic liver disease is a well described manifestati

36 Hepatic cystogenesis in polycystic liver disease is associated with increased le

37 Recently, we discovered that polycystic liver disease is caused by mutations in the p

38 Autosomal dominant polycystic liver disease is characterized by the presenc

39 Polycystic liver disease is genetically linked to protei

40 Polycystic liver disease may complicate autosomal domina

41 ion and biochemical properties of normal and polycystic liver disease mutant forms of hepatocystin we

42 ns were solitary giant liver cysts (n = 16), polycystic liver disease (n = 9), hydatid cyst (n = 6),

43 al hepatic fibrosis (two), cystinosis (one), polycystic liver disease (one), A-1-A deficiency (one),

44 ng mutation in hepatocystin observed in some polycystic liver disease patients produces a protein tha

45 seen in the rare inherited disorder isolated polycystic liver disease (PCLD) and are recognized as th

46 Dominantly inherited isolated polycystic liver disease (PCLD) consists of liver cysts

47 Polycystic liver disease (PCLD) is characterized by cyst

48 Polycystic liver disease (PCLD) is characterized by the

49 of resective and fenestration procedures for polycystic liver disease (PCLD), we present the first se

50 hepatocystin (80K-H, PRKCSH), gives rise to polycystic liver disease (PCLD).

51 In polycystic liver diseases (PCLDs), increased cholangiocy

52 resent review summarizes recent knowledge on polycystic liver diseases (PCLDs), mechanisms of hepatic

53 gulation is a key feature of cystogenesis in polycystic liver diseases (PCLDs).

54 Treatment of polycystic liver disease (PLD) focuses on symptom improv

55 Polycystic liver disease (PLD) is a member of the cholan

56 Polycystic liver disease (PLD) is a rare disorder freque

57 ical trials have shown that in patients with polycystic liver disease (PLD), short-term treatment wit

58 In polycystic kidney disease and polycystic liver disease (PLD), the normally nonprolifer

59 ncreased level of intracranial aneurysms and polycystic liver disease (PLD), which can be severe and

60 cystins (PC1 or PC2/TRPP2) cause progressive polycystic liver disease (PLD).

61 apies for polycystic kidney disease (PKD) or polycystic liver disease (PLD).

62 Polycystic liver diseases (PLD) are inherited disorders

63 Autosomal dominant polycystic liver disease results from mutations in PRKCS

64 The laparoscopic management of polycystic liver disease should be reserved for patients

65 Polycystic liver diseases, the most important of which a

66 d from healthy individuals and patients with polycystic liver disease to reproduce the effects of the

67 We ascertained two large families with polycystic liver disease without kidney cysts and perfor